Nuzenio

Tradingview Keros Therapeutics

Tradingview Keros Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 4 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside - TradingViewTradingView · Tue, 04 Aug 2026 13:20:05 GMTKeros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Tue, 04 Aug 2026 12:00:25 GMTKeros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingViewTradingView · Mon, 03 Aug 2026 20:21:01 GMTKROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingViewTradingView · Mon, 03 Aug 2026 20:04:27 GMT

Timeline

Tue, 04 Aug 2026 13:20:05 GMTKeros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside - TradingView
Tue, 04 Aug 2026 12:00:25 GMTKeros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Mon, 03 Aug 2026 20:21:01 GMTKeros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Mon, 03 Aug 2026 20:04:27 GMTKROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Keros Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.